Clinical trials: Androgens
Triple Negative Breast Cancer
Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer
To facilitate the clinical testing of seviteronel and dexamethasone (SEVI-D) in combination with docetaxel in androgen receptor (AR) positive triple-negative breast cancer.
- Trial name
- 4CAST (NCT04947189)
- Testing
- Seviteronel-D (Seivteronel in combination with dexamethasone), Docetaxel
- Where
- Australia
- Volunteers
- 65 people
- Sponsor
- St Vincent's Hospital, Sydney
Prostate Cancer
Prognostic Value of Androgen Receptor Expression and Mutations Within Oncogenes and Tumor Suppressor Genes in Patients Treated for High Risk Prostate Cancer With Proton Therapy (PRX32)
Retrospective Review Study for Prognostic Transcriptional Output Related to Androgen Receptor Expression in Patients Treated for High Risk Prostate Cancer with Proton Therapy
- Trial name
- PRX32 (NCT03296124)
- Where
- United States
- Sponsor
- University of Florida
Acne Vulgaris
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
This study is designed to determine the hypothalamic-pituitary-adrenal (HPA) axis suppression potential and pharmacokinetic (PK) properties of CB-03-01 Cream, 1%, applied every twelve hours for two weeks, in pediatric patients 9…
- Trial name
- NCT02720627
- Testing
- cortexolone 17α-propionate
- Where
- 10 sites in United States, Poland
- Volunteers
- 27 people
- Sponsor
- Cassiopea SpA
Prostatic Neoplasms
A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer
The purpose of this study is to evaluate how well JNJ-101556143 plus Best Supportive Care (BSC) improves overall survival (the length of time a participant remains alive) compared with placebo plus BSC in participants with…
- Trial name
- NCT07906717
- Testing
- JNJ-101556143, Best Supportive Care
- Where
- 4 sites in United States, Israel
- Volunteers
- 400 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
The current protocol will examine the use of a plasmid DNA vaccine encoding AR, alone or with T-cell checkpoint blockade, to induce and/or augment therapeutic T-cells following androgen deprivation in patients with newly…
- Trial name
- NCT04989946
- Testing
- Degarelix, pTVG-AR, Nivolumab
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Wisconsin, Madison
High Risk Prostate Cancer
PRospective Observational Study of STereotactic Body rAdiation Therapy With Androgen Deprivation Therapy for Organ-confined High-risk Prostate Cancer: the PROSTAR Trial
Prostate Cancer (PCa) is the second most common malignancy and the 5th common cause of cancer-related mortality in men worldwide.
- Trial name
- PROSTAR (NCT06949254)
- Where
- 3 sites in Italy
- Volunteers
- 49 people
- Sponsor
- Istituto Clinico Humanitas
Salivary Gland Cancer, Salivary Duct Carcinoma
PSMA-PET Imaging Before and After ADT in Advanced SDC Patients
Explorative study, which evaluates the effect of androgen deprivation therapy (ADT) on the PSMA ligand uptake on 68Ga-PSMA-PET/CT in salivary duct carcinoma patients.
- Trial name
- ADT-SCAN (NCT04214353)
- Testing
- 68Ga-PSMA-PET/CT, 18FDG-PET/CT
- Where
- Netherlands
- Volunteers
- 14 people
- Sponsor
- Radboud University Medical Center
Hypogonadism, Contraception
The Effects of Testosterone on Prostate Tissue (ACYP-1)
The purpose of this research study is to understand the effects of testosterone on the prostate. This knowledge will be used to help in the development of a safe male hormonal contraceptive and may impact the development of…
- Trial name
- ACYP-1 (NCT00161486)
- Testing
- Testosterone gel, Acyline
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Washington
Prostate Cancer, Prostate Adenocarcinoma
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer
This is a study with the combination of androgen deprivation therapy (ADT) and docetaxel with the addition of enzalutamide in the treatment of subjects with metastatic prostate cancer.
- Trial name
- NCT03246347
- Testing
- ADT+Docetaxel+Enzalutamide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wake Forest University Health Sciences
Prostatic Neoplasms, Neoplasm Metastasis
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.
- Conditions
- Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs
- Trial name
- CYCLONE 3 (NCT05288166)
- Testing
- Abemaciclib, Abiraterone, Prednisone or Prednisolone
- Where
- 266 sites in United States, Argentina and 22 more
- Volunteers
- 925 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer
Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy
This is a Phase 2, open-label study in subjects with androgen-independent prostate cancer who have progressed following treatment with an LHRH agonist. Up to 22 subjects will be enrolled.
- Trial name
- NCT00100243
- Testing
- Plenaxis
- Where
- 7 sites in United States
- Volunteers
- 22 people
- Sponsor
- PRAECIS Pharmaceuticals Inc.
Androgen Receptor Positive, Locally Advanced Salivary Gland Carcinoma
Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
This phase II trial studies how well enzalutamide works in treating patients with androgen receptor positive salivary cancers that have spread from where it started to nearby tissue or lymph nodes (locally advanced) or have…
- Conditions
- Androgen Receptor Positive, Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Salivary Duct Carcinoma
- Trial name
- NCT02749903
- Testing
- enzalutamide
- Where
- 287 sites in United States
- Volunteers
- 46 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7
Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
This phase IIB trial studies how well enzalutamide and paclitaxel before surgery works in treating patients with stage I-III androgen receptor-positive triple-negative breast cancer.
- Conditions
- Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7
- Trial name
- NCT02689427
- Testing
- Axillary Lymph Node Dissection, Enzalutamide, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Castrate-Resistant Prostate Cancer
Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
This study is designed to assess the safety and tolerability of atezolizumab when given in combination with radium-223 dichloride in participants with metastatic CRPC who have progressed after treatment with an androgen pathway…
- Trial name
- NCT02814669
- Testing
- Atezolizumab, Radium-223 Dichloride
- Where
- 17 sites in United States
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Healthy
Effect of Dihydrotestosterone (DHT) on Prostate Tissue [Short Title: DHT-3]
The purpose of this research study is to understand the effects of a male hormone normally made in the body called Dihydrotestosterone (DHT) on the prostate gland that is located under the bladder.
- Trial name
- DHT-3 (NCT00490022)
- Testing
- Dihydrotestosterone (DHT) gel (0.7%)
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Washington
Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma
PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer
This phase I trial studies the side effects and best dose of multitargeted tyrosine kinase inhibitor PLX3397 (PLX3397) when given together with radiation therapy and antihormone therapy in treating patients with prostate cancer…
- Conditions
- Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
- Trial name
- NCT02472275
- Testing
- Antiandrogen Therapy, Laboratory Biomarker Analysis, Multitargeted Tyrosine Kinase Inhibitor PLX3397
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
In Vitro Fertilization
To Evaluate The Anrogens and Ovary Function in In Vitro Fertilization
Because the society convention is changed, people are late for getting married, leading to increasing the bearing age in women. According to the previous study, if the age is over 30, the oocyte number in ovary has left only 10％…
- Trial name
- NCT01600794
- Volunteers
- 1,000 people
- Sponsor
- Taipei Medical University WanFang Hospital
Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7
Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer
This phase I trial is studying the side effects and best dose of ipilimumab when given with sargramostim in treating patients with metastatic prostate cancer.
- Trial name
- NCT00064129
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
The purpose of this study is to determine the benefit of enzalutamide versus placebo as assessed by overall survival and progression-free survival in patients with progressive metastatic prostate cancer who have failed androgen…
- Trial name
- PREVAIL (NCT01212991)
- Testing
- Enzalutamide
- Where
- 269 sites in United States, Australia and 20 more
- Volunteers
- 1,717 people
- Sponsor
- Pfizer
Prostate Cancer
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
The purpose of this phase 3B trial was to see how well a new trial drug (degarelix) works in terms of reducing the size of the prostate volume in prostate cancer patients who were scheduled to undergo subsequent radiotherapy for…
- Trial name
- NCT00833248
- Testing
- Degarelix, Goserelin, Bicalutamide
- Where
- 66 sites in United States, France and 5 more
- Volunteers
- 246 people
- Sponsor
- Ferring Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.